Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

GLENMARK PHARMACEUTICALS LTD.

NSE : GLENMARKBSE : 532296ISIN CODE : INE935A01035Industry : Pharmaceuticals & DrugsHouse : Glenmark

BSE2049.7559.15 (+2.97 %)

PREV CLOSE ( ) 1990.60

OPEN PRICE ( ) 1990.60

BID PRICE (QTY) 2048.15 (7)

OFFER PRICE (QTY) 2050.25 (17)

VOLUME 15431

TODAY'S LOW / HIGH ( )1990.60 2055.15

52 WK LOW / HIGH ( )1274.7 2286.15

NSE2050.6059.7 (+3 %)

PREV CLOSE( ) 1990.90

OPEN PRICE ( ) 1990.90

BID PRICE (QTY) 2050.60 (2)

OFFER PRICE (QTY) 2050.80 (23)

VOLUME 719976

TODAY'S LOW / HIGH( ) 1990.90 2055.20

52 WK LOW / HIGH ( )1275.5 2284.8

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 18-11 1977

Management Info

Glenn Saldanha - Chairman Glenn Saldanha - Managing Director

Registered Office

Address B/2 Mahalaxmi Chambers,22 Bhulabhai Desai Road, ,
Mumbai,
Maharashtra-400026

Phone

Email complianceofficer@glenmarkpharma.com

Website www.glenmarkpharma.com

Registrars Details

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)

Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad

Listing : BSE, NSE

NEWS

05Sep Glenmark Pharmaceuticals initiates mul
Glenmark Pharmaceuticals has initiated a multi-country (ex-China) Phase..

02Sep Glenmark Pharmaceuticals’ arm to launc
Glenmark Pharmaceuticals’ US-based subsidiary -- Glenmark Pharmaceutical..

02Sep Glenmark Pharmaceuticals informs about
Glenmark Pharmaceuticals has informed that it attached media release tit..

21Aug Glenmark Pharma makes remaining invest
Glenmark Pharmaceuticals has made the remaining investment of Rs 0.24 cr..

21Aug Glenmark Pharma gains on making remain
Glenmark Pharmaceuticals is currently trading at Rs. 1943.00, up by 20.0..

Financials

Rs. in Millions

	QTR Jun 25	ANNUAL 25
Net Profit	3302.26	16103.5
Gross Profit	4011.65	21540.18
Operating Profit	7974.94	26005.46
Net Sales	23949.28	92264.09

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Neuland Laboratories (BSE) 14788.80 (1.25%)	M.Cap ( in Cr)18962.19
Astrazeneca Pharma I (BSE) 9152.90 (0.70%)	M.Cap ( in Cr)22875.00
Acutaas Chemicals (BSE) 1479.90 (3.83%)	M.Cap ( in Cr)12135.02
Hester Biosciences (BSE) 2142.05 (2.16%)	M.Cap ( in Cr)1831.06
Blue Jet Healthcare (BSE) 744.20 (4.99%)	M.Cap ( in Cr)12909.30

Shareholding Pattern

	PROMOTERS	46.65%
	MUTUAL FUNDS/UTI	15.55%
	NON-INSTITUTION	15.06%
	FI/BANKS/INSURANCE	0.46%
	GOVERNMENT	0.04%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
Mirae Asset Healthc...	6.38
HDFC Pharma and Hea...	5.53
Tata Nifty MidSmall...	4.47
Motilal Oswal Nifty...	4.44
UTI Healthcare Fund...	3.99
Invesco India Midca...	3.97
Bajaj Finserv Healt...	3.51

Risk Disclosures on Derivatives

Smart Quotes

GLENMARK PHARMACEUTICALS LTD.